Rents down across greater Townsville
In good news for tenants, rents dropped or remained stable across half of the Townsville region in the May quarter, while the majority of increases were sitting below 6 per cent.
The latest PropTrack data showed in the past three months Greater Townsville house rents were down across nine suburbs, stable across a further six and up across 15.
In the unit market, rents were down in three suburbs, stable in seven and up in seven.
The biggest drop was in the North Ward house market where the median rent fell 8 per cent in the May quarter to sit at $388 per week.
Next was the Aitkenvale unit market where the average rent dropped 5 per cent in the past three months to $380, followed by the house market in Douglas with rents down 4 per cent to a median of $530.
The largest increase was in the West End unit market where the median rent was up 8 per cent since February to $388, followed by the Rosslea unit market, up 5 per cent to a median of $400, and the Townsville City unit market, up 5 per cent to a median of $550.
REA Group economist Anne Flaherty said investor activity in Townsville may have helped stabilise the local rental market.
'Townsville has seen a surge in investor interest and I think it's one of the things that has increased the total number of rental properties in Townsville,' she said.
'We do know if you see a surge in investor activity it can slow down rent growth.'
Real Estate Institute Queensland data from the March quarter showed the vacancy rate in Townsville was sitting at 1 per cent, down from 1.2 per cent in the December 2024 quarter and in line with the September 2024 quarter figure.
REIQ CEO, Antonia Mercorella said low vacancy rates such as the 1 per cent in Townsville were concerning.
'The REIQ classifies a 'healthy' vacancy rate as between 2.6-3.5 per cent to sustain a stable rental market that caters to population growth and natural housing mobility,' Ms Mercorella said.
'The state wide vacancy rate remains tight at 0.9 per cent as of the March 2025 quarter, but has hovered around a critically low 1 per cent since December 2023.
'In many parts of the state, vacancy rates are even lower, indicating persistent pressure on supply and ongoing rental stress.'
The PropTrack data showed in Queensland, rent prices decreased in 218 house or unit markets, and remained stable in a further 274 suburbs across the May quarter.
Ms Flaherty said she was surprised to see 35 per cent of Queensland record rent decreases.
'It's good to see … a bit of stabilisation in rents,' she said.
'We have seen a significant slowdown in the pace of rental growth and some rents even moving backwards is good news for renters.
'The levels that rents were previously increasing were very challenging for a lot of households and well out of the ordinary.
'To now be in a situation where rent growth is in line with the historical average levels is a good thing.'
Ms Mercorella said rent decreases and stabilisation across Queensland suggested the market may have reached an affordability ceiling, prompting both lessors and tenants to recalibrate.
'Lessors are increasingly aware that each week a rental property sits vacant, it comes at a cost, and many are making pragmatic decisions around pricing to secure consistent, sustainable long-term tenancies,' she said.
'Property managers are reporting more subdued letting activity, longer days on market, and lessors being more careful with tenant selection.
At the same time, tenants are staying put for longer where they can, recognising the value and stability of renewing existing leases in an uncertain market.'
TOWNSVILLE'S BIGGEST RENT DECREASES, MAY 2025 QUARTER
Property type Suburb Rent_May_2025 Rent_Feb_2025 QoQ
House North Ward $600 $650 -8%
Unit Aitkenvale $380 $400 -5%
House Douglas $530 $550 -4%
House West End $535 $550 -3%
House Charters Towers City $370 $380 -3%
House Ingham $370 $380 -3%
House Mundingburra $540 $550 -2%
House Cosgrove $560 $570 -2%
Unit Kirwan $385 $390 -1%
House Oonoonba $490 $495 -1%
TOWNSVILLE'S BIGGEST RENT INCREASES, MAY 2025 QUARTER
Property type Suburb Rent_May_2025 Rent_Feb_2025 QoQ
Unit West End $388 $360 8%
Unit Rosslea $400 $380 5%
Unit Townsville City $550 $525 5%
House Condon $490 $470 4%
House Ayr $375 $360 4%
Unit Ingham $295 $285 4%
Unit Idalia $460 $450 2%
House Gulliver $480 $470 2%
House Rasmussen $480 $470 2%
House Heatley $480 $470 2%
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
32 minutes ago
- News.com.au
Electrical Trades Union seeks to block vote on train deal that ended months of Sydney strikes
The Electrical Trades Union is seeking to halt a vote on a new enterprise agreement for tens of thousands of rail workers after months of industrial action, claiming it was unfairly left out of 11th-hour meetings. The ETU broke with the Combined Rail Unions last month after the CRU, led by the Rail, Tram, and Bus Union, reached an in-principle agreement with the state government over Sydney and NSW Trains staff. The agreement is supposed to be put to a vote of union members following an order by the Fair Work Commission but could be delayed following an application by the ETU before the commission on Friday. Lawyers representing the ETU claimed during an hours-long hearing that neither Sydney and NSW Trains nor the RTBU had engaged in legally mandated good-faith bargaining during the final days of negotiations. The union, which represents electricians, claims it was excluded from a meeting in late May between the CRU and the state government, which later held three days of meetings with the ETU in early June. The meetings centred on two differences between the ETU and the RTBU that led to the ETU objecting to the pay deal, chiefly the restructuring of competency scales for trade-related staff, known as uplifting. The uplift was granted to 'non-trade' employees under the proposed deal, with the ETU seeking to have the same measure applied to electricians – something it claims is a longstanding desire of the ETU. The rail agencies and the RTBU object to the measure that they say was put forward after negotiations had ended, with Sydney Trains executive Fatima Abbas stating it would impact about 350 workers. The commission was told it wouldn't matter if the uplift cost '$1m or $100m', the rail agencies were not seeking to 'increase the package and consider it the final offer', their lawyer told the court on Friday. 'There are 13,500 employees that will be covered by this agreement. The majority of bargaining representatives support and agree to the final package. If the applicant refuses, the package will not change,' he said. RTBU lawyer Leo Saunders told the commission that the union claimed the ETU had 'excluded themselves' from meetings, and it hadn't put the uplift as a 'formal claim' previously. The possibility of a delay comes after months of negotiations and brinkmanship between the CRU and the RTBU and the state government, including rounds of industrial action and court orders. Following a cooling-off period mandated by the commission earlier this year, a breakthrough in talks came after a fallen wire at Strathfield sparked days of chaos across Sydney's rail network in May. The Full Bench of the Fair Work Commission will deliver their judgment at 4.30pm.
News.com.au
an hour ago
- News.com.au
Scott Power: ASX stocks fall as investors hear mixed news from Cochlear
ASX heath sector falls 1.1% over past five days, while broader markets flat as Middle East tensions flare Cochlear downgrades full-year profit expectations but launches a world first Monash IVF head Michael Knaap resigns after another embryo mix-up Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. It was a big week of news for the ASX healthcare sector with the bourse's fourth largest biotech Cochlear (ASX:COH) downgrading its FY25 net earnings ~4% to $390-400 million, compared with prior guidance in February of $410-430m, on "slower-than-expected sales growth over the last few months". Morgans' healthcare analyst Derek Jellinek wrote in a note to clients consensus for the hearing tech company sat at $411m with Morgans at $412m. While Cochlear continues to expect implant units to grow ~10% in FY25, growth will be weighted to emerging markets as developed market growth has been impacted by slower-than expected market growth and a "small loss" of market share in a few countries. Cochlear now expects services revenue to decline by low double-digits compared to prior expectations for a single-digit decline. "COH believes ongoing work to identify and connect with recipients who could benefit from the latest sound processing technology, combined with the introduction of the new off-the-ear Nucleus Kanso 3 sound processor, which is expected to launch in EU and APAC mid-Jun-25, should lift services revenue in FY26," Jellinek wrote. Following a disappointing H1 FY25 result, Morgans highlighted risks in the services segment (around 25% of sales), driven by slower-than-expected uptake of the Nucleus 8 sound processor, which was launched in FY23, and cost-of-living pressures delaying device replacements. But in some positive news, Cochlear also announced the launch of Nucleus Nexa, the world's first and only smart cochlear implant system, saying it was the "outcome of a 20 year investment in R&D". "A couple of key features include upgraded firmwear, the smallest sound processor and internal memory so that has actually countered the profit downgrade they've announced," Power said. Morgans has a hold rating on Cochlear with a 12-month target price of $285.55. Monash chief quits following another embryo mixup A new acting CEO has been appointed to steer the troubled Monash IVF Group (ASX:MVF), which fell ~27% on Tuesday after reporting another embryo implant bungle. Monash announced on Thursday CEO and managing director Michael Knaap had resigned with CFO and company secretary Malik Jainudeen appointed acting CEO. In the latest incident a patient's own embryo was mistakenly transferred to them, rather than their partner's embryo as specified in the treatment plan at Monash's Clayton laboratory in Melbourne on June 5. Monash said it was conducting an internal investigation to determine the cause of the incident and notified the relevant assisted reproductive technology (ART) regulators, the Victorian health regulator and its insurers. It comes after Monash revealed in April a woman had given birth to a baby that was not hers after receiving the wrong embryo at a Brisbane clinic. An independent review by Fiona McLeod AO SC regarding that incident is currently ongoing and has been extended, with the findings yet to be disclosed. Monash confirmed that its updated profit guidance, issued on May 20, remains unchanged, projecting an underlying NPAT of $27.5 million. Morgans maintains a speculative buy on Monash with a 12-month target price of $1. Israel strikes on Iran add to market uncertainty At 1.45pm on Friday the S&P/ASX 200 Health Care index was down 1.1% for the past five days, while the benchmark ASX 200 was flat for the same period. Markets took a tumble on Friday after reports of Israel strikes against Iran's nuclear sites with the Middle East bracing for retaliation. Power said the escalating conflict adds further complexity to global equity markets still very much being driven by macroeconomic factors and geopolitical tensions. "Markets are still very much broader macro driven including with US President Donald Trump's trade and regulatory policies," Power said. "Investors will now be closely monitoring the escalating tensions in the Middle East." Power's Powerplay: EBR completes raise, starts US rollout EBR Systems (ASX:EBR) is Power's stock of the week after announcing completion of a share purchase plan (SPP) and that the first US commercial patients have been implanted with its WiSE CRT System, the world's only wireless solution for pacing the left side of the heart. The procedures took place at St David's Medical Centre and the Cleveland Clinic, two of several leading US institutions participating in this pilot release of the WiSE CRT System, which was approved by the FDA in April. EBR said the cases represented two of the main indications for WiSE. "Clearly, the first commercial patients implanted with WiSE is a key milestone, as EBR has officially transitioned from a pure R&D focus to a commercial entity," Jellinek wrote in a note to clients. He said importantly, the implants were done in advance of reimbursement and the limited market release of WiSE, which remained on track for October, showcasing the unmet medical need in the initial US$3.6m total addressable market and belief in use of the device. "As this device is a novel treatment option requiring physician education, we view the LMR, targeting key heart failure centres in the US, as an appropriate strategic way to build familiarity and experience, prior to full market release," he wrote. "We see sales surpassing US$80m into CY29. "While certainly not a 'hockey stick', we believe it is a methodical, stage-gated rollout to build strong physician support and closely monitor clinical outcomes, helping to pique interest from any would-be suitor." The company also announced today it had finished its SPP raising $xxm and adding to a fully underwritten Institutional Placement raising $55.9m completed in May. Proceeds from the capital raise will be used to advance its US commercialisation strategy for WiSE. Morgans has a buy rating and 12-month target price of $2.86. Two positive studies for Avita Wounds management company Avita Medical (ASX:AVH) has announced the first clinical publication of its Cohealyx product, which is a collagen-based dermal matrix, in the Journal of Surgery. The publication includes two positive case reports on patients with complex hand wounds treated with Cohealyx. In both instances, the patients sustained full-thickness burns following syncopal episode (temporary loss of consciousness due to a drop in blood flow to the brain). The study showed significant acceleration of wound bed vascularisation and autograft readiness, achieving readiness within five to 10 days compared to the typical two to four weeks. "Clearly, a small sample size and this publication represents the first clinical validation of AVH's preclinical findings but it's a strong start and likely the first of many case-studies to come," Morgans' healthcare analyst Iain Wilkie wrote in a note to clients Avita also announced a new study of its flagship spray-on skin treatment Recell showed it reduced hospital stays by 36% compared to traditional skin grafts. Presented at the British Burn Association's annual meeting, the US-based study analysed outcomes for more than 6,300 patients treated with Recell between 2019 and 2024. All patients had burns covering less than 30% of their total body surface area. The findings showed Recell patients spent on average 6.2 fewer days in hospital, delivering an estimated $300m in healthcare savings over the five-year period. Wilkie wrote that the share price had continued to remain weak following series of missed guidance expectations and dwindling cash reserves. "The point with Avita is they've expanded their product range to treat more of the wound complex and what the market is concerned about is do they need to raise additional funds," Power said. "They've told the market they can see a pathway through to profitability or breakeven by the fourth quarter of this calendar year so as each quarter rolls on we will get more confident that they're able to achieve that." Morgans has a speculative buy rating on Avita and 12-month target price of $3.76. Imricor gets CE Mark for NorthStar Mapping System Imricor Medical Systems (ASX:IMR) has received CE mark (European) certification for its NorthStar Mapping system under the new, more stringent European Union Medical Device Regulations (MDR). NorthStar has been approved as a Class IIa medical device with the certification received ahead of schedule. Imricor is advancing technology for real-time interventional cardiac magnetic resonance (iCMR) ablations, enabling cardiac ablation procedures to be guided by live MRI imaging instead of traditional x-ray fluoroscopy. NorthStar is a key component of its product offering. The certifications follows on from recent European approvals received for its Advantage-MR EP Recorder/Stimulator (Advantage-MR), and its second generation Vision-MR Ablation Catheter. "Imricor will now phase out first generation products approved under the old EU regulations, replacing them with new MDR approved devices," Power said. "We expect sales momentum to steadily build over coming quarters." Power said next catalysts to watch for include additional sales orders in Europe and Middle East and US FDA approval for NorthStar. Imricor is also undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, which it hopes to achieve in 2025. In Europe, where Imricor has already received regulatory approval for atrial flutter, the company has started a pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT). Morgans has a speculative buy on Monash and 12-month $2.28 target price. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
News.com.au
an hour ago
- News.com.au
Syndicator Steve Vardy says his four runners at Rosehill Gardens on Saturday are ‘proof you don't need to pay big money to have a chance in racing'
Sydney racing needs a good news story so welcome to the stage syndicator Steve Vardy's 'Fab Four' of Winning Proposal, Crafty Eagle, Hell Of A Fox and Hellbent For You. In the last few weeks, the racing news cycle has been dominated by the failed Rosehill sale proposal, talk of boardroom coups and industry disunity but these four racehorses are a welcome and positive advertisement for the sport. Winning Proposal, Crafty Eagle, Hell Of A Fox and Hellbent For You were each acquired for a modest price, have already returned a profit with considerable interest for their owners, and are winning chances at Rosehill Gardens on Saturday. 'I only set up the syndication business (Vardy Thoroughbreds) five years ago and this is the first time we have had four runners at a Sydney Saturday meeting,'' Vardy said. 'For a syndicator, it is a dream to have your colours going around in Sydney racing and these four horses are proof you don't need to pay big money to have a chance in this game. 'We try to buy horses at value prices and hopefully provide our clients with some fun at the races and a return on their investment.'' The cheapest of the 'Fab Four' is Winning Proposal, a $50,000 purchase from the Inglis Premier Sale who has already amassed $217,900 prizemoney. She's a $13 chance in the Asahi Super Dry Handicap (1100m). Then there's Hell Of A Fox, a $60,000 Inglis Classic Sale graduate who has amassed $95,600 in earnings. She's chasing a fourth consecutive win in the TAB Highway (1400m). Vardy purchased Crafty Eagle for $70,000 at an Inglis Ready2Race sale and he's the clubhouse leader of the quartet with prizemoney of $235,625. He's at $19 for the Captivant At Kia Ora Handicap (1300m). Hellbent For You was the most expensive Vardy purchase although she was knocked down for only $75,000 at the Inglis Classic Sale. She has won four races and $167,850 already, and is rated a $15 chance in the Toyota Forklifts Handicap (1300m). Be honest... who had given up on Hellbent On You before she snuck through to win with @mcacajamez in the saddle for @JTRacingRwik?! That's a win and a half ðŸ'° @aus_turf_club — SKY Racing (@SkyRacingAU) May 14, 2025 Vardy said all four were 'good each-way chances'' at Rosehill. 'Winning Proposal ran really well at Gosford first-up, she ran third and was unlucky not to have won, then she couldn't pick her feet up in the very heavy going at Randwick last start,'' Vardy said. 'Hell Of A Fox took a while to break her maiden but she has been such a success story since we sent her to Luke Pepper to train. 'Crafty Eagle is a quirky horse but John Thompson has taken the winkers off and mixed his training. If he's on his game, he can run a really good race. 'Hellbent For You is another who found the track like glue at Randwick last start but she never stopped trying. She's such a genuine mare and we expect her to run a competitive race.'' Hell Of A Fox with a hell of a finish! ðŸ'¥ The Luke Pepper trained filly makes it back-to-back wins! ✌ï¸� — SKY Racing (@SkyRacingAU) May 18, 2025 â– â– â– â– â– Bookies cold on Smith galloper's chances Icebreaker is undefeated in three starts this season, he's drawn the rails barrier, is trialling well – but he's the rank outsider at $41 for the Racing And Sports Handicap (1400m). Trainer Matthew Smith isn't worried the price assessors have dismissed Icebreaker's chances as the grey four-year-old has done everything right in preparation for his Rosehill return. 'He's trialling nicely, I can't fault him, he's coming up 'good','' Smith said. 'He likes wet tracks which is a help to him, too.'' Icebreaker is resuming after reeling off three successive wins over the Canberra 1600m course late last year. 'There was a perfect sequence of races for him so we kept going back to Canberra,'' Smith explained. 'He started off in a class 1, then he ran in two (benchmark) 70 races. They just fitted nicely into his preparation. 'After he won his third race in a row, we gave him a good spell and he's come back in great order. 'The 1400m on Saturday might be a bit short but it might not either as he's nice and fresh. I think he can run well.'' Jockey challenge favourite @djgibbons22 kicks off the @WyongRaceClub card with a win on Icebreaker 🧊 — SKY Racing (@SkyRacingAU) April 11, 2024 Icebreaker is Smith's solo Rosehill runner while the trainer also has just the one starter at Eagle Farm – tough stayer True Marvel in the Group 2 $400,000 Brisbane Cup (3200m). True Marvel, rising 10-year-old, is a specialist at the marathon trip and two years ago ran second in the Sydney Cup behind Explosive Jack, third in Selino's Brisbane Cup, and ran a commendable eighth in the Melbourne Cup won by Without A Fight. But after missing all of 2024 with injury, True Marvel has had six starts this preparation and indicated he was close to his best again with his fourth behind Diwali in the Sandown Cup at 3200m last start. Diwali relishes the two-mile test of the Listed Sandown Cup â�ï¸� @GavinBedggood 's strong form continues ðŸ'¥ — (@Racing) June 1, 2025 • 'True Marvel is going super, he's a true stayer and needs those genuine staying trips,'' Smith said. 'He ran well last start when nothing really went right for him during the race and I think he can run a very good race in the Brisbane Cup. 'He's been a ripping old horse, he loves training and racing but there are not enough 3200m races for him. But he's won a lot of money for his owners ($942,715) and it would be great if he could get to $1 million on Saturday.'' â– â– â– â– â– Another Group 1 win? That'd be Cool Max Whitby has enjoyed plenty of success as an owner-breeder in racing but admitted it would be 'next level' if his brilliant two-year-old Cool Archie can win the Group 1 $1 million JJ Atkins (1600m) at Eagle Farm. 'I can't tell you what it would mean to me if Cool Archie can win the JJ Atkins,'' Whitby said. 'I've waited 20 years since Savabeel to get another potential stallion and if Cool Archie wins the Group 1 it would be really special. 'Cool Archie is a grandson of Savabeel and he's trained by Chris Munce, who used to ride Savabeel, so it's all there. I'm just super proud of this colt.'' After reeling off four successive wins including the Listed Dalrello Stakes and back-to-back Group 2 wins in the Champagne Classic and BRC Sires Produce Stakes, Cool Archie is the $3.60 favourite for the JJ Atkins. A barnstorming win by Cool Archie in the G2 BRC Sires' Produce Stakes, and that's four in a row to the @munceracing galloper! 🙌 @BrisRacingClub — SKY Racing (@SkyRacingAU) May 31, 2025 • 'I'm never short of confidence in anything I try to do in life but I'm trying to rein myself in a little with Cool Archie,'' Whitby said. 'All I can tell you is my trainer is very happy, the horse is the same weight as he was last start, he's drawn OK in nine, he handles good tracks and we think he will run the 1600m easily. 'And my jockey, Martin Harley, is so optimistic it is unbelievable. He's going over to ride at Royal Ascot after this weekend so I hope we can give him a Group 1 win before he leaves for England.'' • 2025 JJ Atkins tips, runner-by-runner form analysis â– â– â– â– â– 5 YEARS AGO Tyzone, runner-up in the Stradbroke Handicap to Trekking the previous year, went one better when he scored a popular win in Queensland's premier race for trainers Toby and Trent Edmonds, defeating Madam Rouge at Eagle Farm. It was a dual celebration for local trainers when Rob Heathcote's brilliant Rothfire raced away with the JJ Atkins. Love You Lucy, a $41 outsider, won the Dane Ripper Stakes but the Brisbane Cup was not run that year due to the Covid pandemic. At Rosehill, the Chris Waller-trained Wu Gok won the Winter Cup. • A thrilling finish in the TAB Stradbroke Handicap as Tyzone who ran second in last year's race has come back to win the 2020 edition for @EdmondsRacing and Robbie Fradd @TrentEd1 @RaceQLD @BrisRacingClub — SKY Racing (@SkyRacingAU) June 6, 2020 10 YEARS AGO The Ciaron Maher-trained Srikandi scored a career-best win over Boban in the Stradbroke Handicap, run that year at Doomben. Srikandi backed up two weeks later to make it successive Group 1 wins in the Tatt's Tiara. Chris Waller's Press Statement maintained his unbeaten record in the JJ Atkins. Later that year, Press Statement won a second Group 1 in the Caulfield Guineas. Jetset Lad was an upset winner of the Brisbane Cup and the Lee Freedman-trained Hazard won the Dane Ripper Stakes. Kerrin McEvoy rode Kapour, also trained by Maher, to win the Winter Cup. 20 YEARS AGO St Basil saved the best for last with the 13th and final win of his race career in the Stradbroke defeating Perfect Promise and Shamekha. Darci Brahma finished powerfully to win the TJ Smith Stakes (now JJ Atkins), the first of five Group 1 wins during his career. Darci Brahma then became a leading New Zealand-based stallion. Portland Singa, trained by Neville McBurney, won the Brisbane Cup and Gerald Ryan's Our Sweet Moss won the Dane Ripper. The late Jack Denham prepared Verb to win the Winter Cup.
